Abrupt cessation of US funds could lead to 3 million HIV-related deaths: WHO
HQ Times March 18, 2025: The strides made in disease containment and eradication such as malaria, HIV, and tuberculosis in the last 20.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Times March 18, 2025: The strides made in disease containment and eradication such as malaria, HIV, and tuberculosis in the last 20.
HQ Team March 17, 2025: Celon Pharma’s human trial with PDE10A inhibitor, CPL’36, has achieved statistically significant reductions in involuntary movements caused by.
HQ Team March 17, 2025: AstraZeneca has announced plans to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies, for up to.
HQ Team March 17, 2025: The Phase III CALYPSO trial, led by Alexion, AstraZeneca Rare Disease, has shown promising results for eneboparatide (AZP-3601),.
HQ Team March 15, 2025: A decade of research at MIT’s Picower Institute for Learning and Memory has brought hope to millions battling.
HQ Team March 15, 2025: An Australian man in his forties has become the first person in the world to be discharged from.
March 14, 2025 –The United Nations Commission on Narcotic Drugs (CND) has decided to place five new psychoactive substances and one medicine under.
HQ Team March 13, 2025: The U.S. Food and Drug Administration (FDA) has approved the expanded use of drug eculizumab (marketed as Soliris).
HQ Team March 13, 2025: A study published in the Journal of the American Heart Association reveals that limiting TV viewing to no more than.
HQ Team March 12, 2025: In a significant development for HIV prevention, Gilead Sciences has unveiled promising data from its Phase 1 study.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com